Higuchi, Takashi
Oka, Shomi
Furukawa, Hiroshi
Tohma, Shigeto
Funding for this research was provided by:
Japan Society for the Promotion of Science. (22K16756)
Bristol-Myers Squibb Co. (.)
Mitsui Sumitomo Insurance Welfare Foundation (.)
Takeda Science Foundation (.)
National Hospital Organization (.)
Teijin Pharma Limited (.)
Takeda Pharmaceutical Company Limited (.)
Pfizer Japan Inc. (.)
Merck Sharp and Dohme Inc. (.)
Mitsubishi Tanabe Pharma Corporation (.)
Eisai Co. Ltd. (.)
Chugai Pharmaceutical Co., Ltd. (.)
Astellas Pharma Inc. (.)
Abbott Japan Co. Ltd (.)
Article History
Received: 3 November 2023
Accepted: 3 January 2024
First Online: 4 January 2024
Competing interests
: ST received honoraria from Pfizer Japan Inc., Ono Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical Co., Ltd., Astellas Pharma Inc., AbbVie GK., and Asahi Kasei Pharma Corporation. ST was supported by research grants from Teijin Pharma Limited, Takeda Pharmaceutical Company Limited, Pfizer Japan Inc., Mitsubishi Tanabe Pharma Corporation, Merck Sharp and Dohme Inc., Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Astellas Pharma Inc., and Abbott Japan Co., Ltd. HF received honoraria from Takeda Pharmaceutical Company, Pfizer Japan Inc., Luminex Japan Corporation Ltd., Dainippon Sumitomo Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Ayumi Pharmaceutical Corporation, and Ajinomoto Co., Inc. HF was supported by research grants from Bristol-Myers-Squibb Co., Mitsui Sumitomo Insurance Welfare Foundation established by Mitsui Sumitomo Insurance Co., Ltd., Daiwa Securities Health Foundation established by Daiwa Securities Group Inc., Nakatomi Foundation established by Hisamitsu Pharmaceutical Co., Inc., Takeda Science Foundation supported by Takeda Pharmaceutical Company, and Japan Research Foundation for Clinical Pharmacology run by Daiichi Sankyo. The other authors declare no financial or commercial conflict of interest.